Fate Therapeutics, Inc. (FATE) financial statements (2020 and earlier)

Company profile

Business Address 3535 GENERAL ATOMICS COURT
SAN DIEGO, CA 92121
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1001918992654954
Cash and cash equivalents1001918989654954
Short-term investments   4   
Receivables 1     
Other undisclosed current assets12714141111
Total current assets:22720510393665055
Noncurrent Assets
Operating lease, right-of-use asset23
Property, plant and equipment11532211
Long-term investments and receivables39      
Long-term investments39      
Contract with customer, asset, net12
Restricted cash and investments0000000
Other noncurrent assets010000 
Total noncurrent assets:75832211
TOTAL ASSETS:30221310595685156
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities211595343
Accounts payable6421111
Accrued liabilities151174222
Employee-related liabilities     1 
Deferred revenue3
Debt22 8822
Deferred revenue and credits22200
Contract with customer, liability8
Other undisclosed current liabilities32  0(1)0
Total current liabilities:282711151355
Noncurrent Liabilities
Long-term debt and lease obligation25121531118 
Long-term debt, excluding current maturities 121531118 
Operating lease, liability25
Liabilities, other than long-term debt41124600
Deferred revenue and credits23500
Accounts payable and accrued liabilities 10110 
Deferred revenue4
Contract with customer, liability8
Deferred rent credit 3
Total noncurrent liabilities:292417716180
Total liabilities:5751282230235
Stockholders' equity
Stockholders' equity attributable to parent, including:2451607773382851
Preferred stock0000   
Common stock0000000
Additional paid in capital628446296249180141137
Accumulated other comprehensive income (loss)0(0)(0)(0)   
Accumulated deficit(384)(285)(219)(176)(142)(112) 
Other undisclosed stockholders' equity attributable to parent      (87)
Total stockholders' equity:2451607773382851
Other undisclosed liabilities and equity11     
TOTAL LIABILITIES AND EQUITY:30221310595685156

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenue, net442 1
Gross profit:115442 1
Operating expenses(111)(72)(46)(36)(30)(25)(19)
Operating loss:(101)(67)(42)(32)(28)(25)(18)
Nonoperating income (expense)31(1)(1)(2)(1)(3)
Investment income, nonoperating 0   00
Other nonoperating income (expense)30(1)(1)(2)(1)(3)
Interest and debt expense(2)(2)(0)(2)(2)(1)(1)
Loss before gain (loss) on sale of properties:(100)(68)(43)(35)(32)(27)(21)
Other undisclosed net income21     
Net loss:(98)(67)(43)(35)(32)(27)(21)
Other undisclosed net income attributable to parent  02210
Net loss available to common stockholders, diluted:(98)(67)(43)(33)(30)(26)(21)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss:(98)(67)(43)(35)(32)(27)(21)
Other undisclosed comprehensive income0002   
Comprehensive loss, net of tax, attributable to parent:(98)(67)(43)(33)(32)(27)(21)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: